Dear pharmacist,
Novo Nordisk cordially invites to attend the VIRTUAL LAUNCH OF​

The once-weekly GLP-1 RA treatment unifying superior efficacy and cardiovascular benefits.

Please select one of the three Virtual Launches below that best suits your schedule.

For more information:

Anelle Burger | |

011 202 0598

Guest Speaker:
DR Simon Akerman

Dr Simon Akerman has held the position of Head of Endocrinology at Greys Hospital in Pietermaritzburg since 2015. He has participated in  research that covered the “Varying D-Dimer cut off values and its effect on Sensitivity for VTE exclusion” and the “Clinical characteristics and gonadal pathology in a young girl with 45,XI45XY mosaicism”. In addition, Dr Akerman has been assisting the College of Medicine of South Africa with setting and marketing the Part 2 Objective test since 2016

Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6)(suppl 1):1-28. 2. Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341-354. 3. Pratley RE, Aroda VR, Lingvay I, et al; SUSTAIN 7 Investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4): 275-286. 4. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1- to 3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetesic Metab. 2019;46(2):100-109. 5. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.

S4 Ozempic® – Solution for injection in a pre-filled pen. Ozempic® 0,25 mg and 0,5 mg/dose pen: Each pre-filled pen contains 2 mg semaglutide in 1,5 ml solution. Ozempic® 1 mg/dose pen: Each pre-filled pen contains 4 mg semaglutide in 3 ml solution. Reg. No.: 53/21.13/0497. For full prescribing information, refer to the Patient Information Leaflet approved by the Regulatory Authority.

Novo Nordisk (Pty) Ltd. Reg. No.: 1959/000833/07. 150 Rivonia Road, 10 Marion Street Office Park, Building C1, Sandton, Johannesburg, 2196, South Africa. Tel: (011) 202 0500. Fax: (011) 807 7989. ZA21OZM00024. June 2021.

Novo Nordisk
Novo Nordisk

Ozempic® Semaglutide RSVP

22 JUNE 2021 - 11H30​

Ozempic® Semaglutide RSVP

29 June 2021 - 08h00

Ozempic® Semaglutide RSVP

29 JUNE 2021 - 18H00​